What Happened?
Cambridge, MA-based Amolyt-Pharma Appointed Louis Arcudi as Chief Financial Officer
About the Company
Amolyt Pharma is building on its team`s established expertise in therapeutic peptides development to deliver life-changing treatments to patients suffering from rare endocrine and metabolic diseases. Amolyt Pharma`s programs include AZP-3601, a parathyroid hormone analog, for the potential treatment of hypoparathyroidism and AZP-3404, a peptide with a new and unique mechanism of action, that may restore fat and glucose metabolism. The collaborative Amolyt Pharma team is well-equipped for upcoming milestones and for the adoption of additional programs as made possible by its global network in the field of endocrinology and with support from a strong syndicate of international investors.
About the Person
Louis Arcudi is Chief Financial Officer at Amolyt Pharma. Previously, Louis held various senior HR leadership roles in the industry.
Info Source
News
Short Profile